Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics
Loading...
Citations
Scopus:
Altmetric:
Altmetric::
Download
Associated Records
Authors
File Licence
Editors
Date
2025-11
Source Title
Journal of Personalized Medicine
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI AG
Melbourne Authors
Affiliation
Sir Peter MacCallum Department of Oncology
Melbourne Medical School
Melbourne Medical School
Document Type
Journal Article
Subject Code
Citation
Casan, J. M. L., Ong, X. J., van der Weyden, C., Yannakou, C. K., Zhu, J., D’Souza, C., Neeson, P. & Prince, H. M. (2025). Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics. Journal of Personalized Medicine, 15 (11), https://doi.org/10.3390/jpm15110560.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
Despite recent progress in lymphoma immunotherapy, outcomes for patients with peripheral T cell lymphomas (PTCLs) remain poor. The challenge of PTCLs reflects the profound biological heterogeneity and relative rarity of this disease group and its resistance to conventional chemotherapy, as well as the formidable challenge of generating definitive clinical evidence. However, deepening insight into the immunogenomic and microenvironmental basis of PTCL has revealed diverse mechanisms of immune escape, spanning defects in antigen presentation, apoptotic signaling, adhesion, and extensive tumor microenvironmental remodeling. These vulnerabilities provide a sound rationale for novel immunotherapeutic strategies—checkpoint inhibitors, CAR-T and NK cell platforms, bispecific antibodies, oncolytic viruses, and immunomodulatory agents. Early studies show encouraging but inconsistent activity, and the variability in response highlights the urgent need for biomarker-driven stratification to deliver personalized approaches and clinically meaningful efficacy. This review synthesizes the current literature on the immune dysregulation of PTCLs, as well as advances in PTCL immunotherapy, outlining the biological rationale underpinning these approaches. We discuss approaches to molecular, transcriptomic, and microenvironmental profiling with circulating biomarkers that could enable adaptive trial designs and personalized treatment strategies. Together, these developments chart a path away from empiricism and toward precision therapy in PTCLs.